MRKR Soars As FDA Lifts Hold On MT-401, RYTM Sells Priority Review Voucher, MLND Dumps MLE-301

Today’s Daily Dose brings you news about the FDA lifting the partial clinical hold on Marker Therapeutics’ phase II post-transplant acute myeloid leukemia trial; Rhythm selling its Rare Pediatric Disease Priority Review Voucher for $ 100 million; Hoth Therapeutics’ financing … Read more…

Amb. Bolton: Retaliation For Suspected Russian Hack Has To Be ‘Top Priority’ | MTP Daily | MSNBC

MTP Daily with Chuck Todd | MSNBC SPECIAL NEWS UPDATE: Click today to request your free ACRX discount prescription card and save up to 80% off of your medicine! SPECIAL DONATION REQUEST UPDATE: Please help American Consultants Rx achieve it’s … Read more…